Biolexis and Akston Biosciences announce encouraging results of thermostable 2nd Gen COVID-19 vaccine
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
This agreement is truly remarkable for achieving greater objectives in the projects and addressing larger problems
The deal will be financed by Rs 300 crore of internal accruals and Rs 350 crore of borrowings
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Announces pilot project for rapid, remote diagnosis of tuberculosis
A new course at the Azrieli Faculty of Medicine will focus on tissue regeneration and 3D printing for therapeutic needs
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
Subscribe To Our Newsletter & Stay Updated